Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation Message Board

  • Dooper55 Dooper55 Apr 10, 2012 8:15 AM Flag

    2nd OMS302 Phase 3 clinical trial underway

    Omeros Announces Enrollment In Second Phase 3 Clinical Trial Evaluating OMS302

    –Data from Trial Expected in Second Half of 2012–


    SEATTLE, April 10, 2012 /PRNewswire/ – Omeros Corporation (OMER) today announced that patient enrollment has begun in the Company’s second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery. OMS302, one of Omeros’ proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. In the first Phase 3 clinical trial of OMS302, the drug product demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis (p<0.00001) and reduction of postoperative pain (p<0.00001).

    Like the initial Phase 3 clinical trial, this second Phase 3 trial will enroll approximately 400 patients undergoing cataract surgery or refractive lens exchange. Randomized, double-blind, placebo-controlled and multicenter, this trial will evaluate the same efficacy and safety measures as the earlier successful Phase 2b and Phase 3 clinical trials. Data are expected in the second half of 2012.

    “Given the strength and consistency of the data from the earlier Phase 2b and Phase 3 clinical trials of OMS302, we look forward to reporting results from our second Phase 3 trial later this year,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Our previous OMS302 trials enrolled rapidly, and we expect a similar enrollment rate in this trial. We have begun preparing our NDA and, assuming positive data, are targeting a submission date in the first part of 2013.”

 
OMER
15.50-0.26(-1.65%)Aug 28 4:00 PMEDT